The program's third iteration expands training and capital access countywide. Travis County's new small business support program is designed to provide comprehensive training, coaching, and increased access to capital. This initiative aims to respond to negative economic impacts of the COVID-19 pandemic and its aftermath by strengthening small business practices, resiliency and sustainable growth. This […]

(NYSE:CNC), SAN FRANCISCO, Aug. 08, 2025 (GLOBE NEWSWIRE) — Before the markets opened on July 25, 2025, investors in Centene Corporation (NYSE: CNC) saw the price of their shares decline about 10% in pre-market trading after the company reported disastrous Q2 2025 financial results. The company, a prominent provider of government-sponsored and commercial healthcare services,

Centene Corporation (CNC) Shares Fall ~10% Pre-Market After Reporting Q2 2025 Diluted Loss Per Share, Class Action Lawsuit Over “Inflated Guidance” Pending – Hagens Berman CNC Investors with Losses Encouraged to Contact Hagens Berman GlobeNewswire August 08, 2025 SAN FRANCISCO, Aug. 08, 2025 (GLOBE NEWSWIRE) — Before the markets opened on July 25, 2025, investors

Key opinion leader event and pancreatic cancer clinical data validate decision to engage with regulators on plans for a registration-enabling study New members of the management team bring expertise in progressing clinical programs and executing successful biotech transactions Translational data further elucidate pelareorep's mechanism of action and ability to prime the tumor microenvironment for treatment

(NASDAQ:SRPT), SAN FRANCISCO, Aug. 08, 2025 (GLOBE NEWSWIRE) — On July 24, 2025, the European Medicines Agency (“EMA”) recommended the refusal of the marketing authorization for ELEVIDYS, Sarepta's medication intended for the treatment of Duchenne muscular dystrophy. This news prompted another significant decline in the price of Sarepta (NASDAQ: SRPT) shares. The EMA's recommendation follows

Sarepta Therapeutics (SRPT) Declines Again On EMA Recommendation to Refuse ELEVIDYS Marketing Authorization, Securities Class Action Pending – Hagens Berman GlobeNewswire August 08, 2025 SAN FRANCISCO, Aug. 08, 2025 (GLOBE NEWSWIRE) — On July 24, 2025, the European Medicines Agency (“EMA”) recommended the refusal of the marketing authorization for ELEVIDYS, Sarepta's medication intended for the

(CNSX:MMET.CN),(OTC US:MMETF),(OTCQB:MMETF),(Boerse Frankfurt – Freiverkehr:8NQ),(CNSX:MMET), NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VANCOUVER, British Columbia, Aug. 08, 2025 (GLOBE NEWSWIRE) — Miata Metals Corp. (CSE: MMET) (FSE: 8NQ) (OTCQB: MMETF) (“Miata” or the “Company“) is pleased to announce that, as a result of strong investor demand, the Company has upsized

(NYSE:HIMS), SAN FRANCISCO, Aug. 08, 2025 (GLOBE NEWSWIRE) — On August 5, 2025, investors in Hims & Hers Health (NYSE: HIMS) declined almost 11% in another sell-off after the company disclosed that it would lower revenue recognized per customer specific to its so-called personalized GLP-1 component, a medication the company compounds to treat weight loss.

HIMS Shares Decline Amid Lower Revenue Per Order For GLP-1 Following Novo Nordisk Collaboration Termination, Securities Class Action Pending — Hagens Berman GlobeNewswire August 08, 2025 SAN FRANCISCO, Aug. 08, 2025 (GLOBE NEWSWIRE) — On August 5, 2025, investors in Hims & Hers Health (NYSE: HIMS) declined almost 11% in another sell-off after the company

Miata Metals Upsizes Private Placement to $5 million GlobeNewswire August 08, 2025 NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VANCOUVER, British Columbia, Aug. 08, 2025 (GLOBE NEWSWIRE) — Miata Metals Corp. (CSE: MMET) (FSE: 8NQ) (OTCQB: MMETF) (“Miata” or the “Company“) is pleased to announce that, as a result of